Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
About this item
Full title
Author / Creator
WANG, Yang , YUAN, Xiaobin , Xiong, Jiayan , HAO, Zhidong , PENG, Xingzhe , CHEN, Wanlin , CUI, Lingling , LI, Hua , WANG, Xiulan , HE, Xiangbo , YANG, Min , LIANG, Congxin , Ma, Yongbin , DING, Lieming and MAO, Li
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Journal title
Language
Chinese
Formats
Publication information
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Subjects
More information
Scope and Contents
Contents
肺癌是全世界发病率和致死率最高的恶性肿瘤，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）约占肺癌的85%。间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）重排阳性的NSCLC仅占全部NSCLC 的5%，但预后较差，因此积极的治疗非常迫切。盐酸恩沙替尼胶囊（ensartinib hydrochloride capsule，X-396，商品名贝美纳TM）是第二代ALK抑制剂，对ALK的抑制活性和肺癌中枢神经系统转移的有效性较克唑替尼更强，并且可抑制多个克唑替尼耐药突变位点，临床拟用于治疗克唑替尼耐药的ALK阳性NSCLC。文中对盐酸恩沙替尼胶囊在国内外开展的I期-III期临床试验进行了总结，并对其药理作用、药代动力学和药效...
Alternative Titles
Full title
Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2dc0d9d32b294357bc045f34fac87a63
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2dc0d9d32b294357bc045f34fac87a63
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2020.102.34
